Examkin

Question

Difficulty: MediumBipolar and Related Disorders

A 21-year-old male university student is evaluated in the student health center for worsening fatigue, hypersomnia, and feelings of worthlessness over the past month. He states that he is failing his classes and feels "it would be better if I just went to sleep and never woke up." Review of his medical record reveals a prior psychiatric hospitalization at age 19 for a week-long episode of decreased need for sleep, grandiosity, and reckless spending. He currently takes no medications and uses no illicit substances. The physician is formulating a comprehensive management plan. Which of the following statements regarding his diagnosis and pharmacological management are correct? Select all that apply.

  1. Initiation of quetiapine monotherapy is an appropriate first-line treatment for his current episodeAnswer
  2. B
    Initiation of escitalopram monotherapy is indicated to rapidly target his severe depressive symptoms
  3. C
    Co-administration of a selective serotonin reuptake inhibitor and a monoamine oxidase inhibitor is recommended if initial therapy fails
  4. Baseline renal function and thyroid panel testing should be obtained if lithium therapy is selectedAnswer
  5. E
    The patient's prior one-week history of grandiose symptoms meets the duration criteria for diagnosing schizophrenia

Answer

The correct statements are that quetiapine monotherapy is an appropriate first-line treatment, and that baseline renal function and thyroid panel testing should be obtained if lithium therapy is selected.
This patient's history of a full manic episode (lasting at least 1 week with severe symptoms) confirms a diagnosis of Bipolar I Disorder. He is currently presenting with a severe acute bipolar depressive episode. Quetiapine monotherapy is FDA-approved and widely considered a first-line treatment for acute bipolar depression, as it treats depressive symptoms without a high risk of inducing mania. Alternatively, lithium could be used for treatment; however, because lithium is renally excreted and can cause nephrogenic diabetes insipidus, chronic kidney disease, and thyroid dysfunction (hypothyroidism), standard pre-treatment workup mandates baseline assessment of renal function (BUN/creatinine) and a thyroid panel.

Step-by-Step Solution

1
Identify the patient's primary diagnosis based on psychiatric history.
The patient has a history of a week-long episode of decreased sleep, grandiosity, and reckless spending, which meets the criteria for a manic episode, establishing a diagnosis of Bipolar I Disorder.
Accurate psychiatric diagnosis is required to select appropriate pharmacotherapy and avoid contraindicated medications.
2
Determine the nature of the current presentation.
The patient is currently experiencing a severe major depressive episode with suicidal ideation.
Treatment must specifically target the acute depressive phase without destabilizing the patient's underlying mood disorder.
3
Evaluate the pharmacological options and pre-treatment requirements for bipolar depression.
First-line treatments include quetiapine, lurasidone, or lithium. SSRI monotherapy must be avoided due to the risk of a manic switch. If lithium is chosen, baseline renal and thyroid tests are mandatory.
Standard of care for bipolar depression mandates avoiding unchecked serotonin elevation and monitoring for known organ toxicities of mood stabilizers.

Key Concept

Pharmacological management and pre-treatment workup of acute bipolar depression
Rate this question

Topics

Bipolar and Related Disorders

More questions from this topic